isoniazid (nydrazid) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Isoniazid is a bactericidal agent active against organisms of the genus Mycobacterium, specifically M. tuberculosis, M. bovis and M. kansasii. Isoniazid is recommended for all forms of tuberculosis in which organisms are susceptible. Isoniazid is a prodrug and must be activated by bacterial catalase. Isoniazid inhibits InhA, the enoyl reductase from Mycobacterium tuberculosis, by forming a covalent adduct with the NAD cofactor. The most frequent adverse reactions to isoniazid are those affecting the nervous system and the liver.   NCATS

Chemistry

  • SMILES: NNC(=O)C1=CC=NC=C1
  • InChIKey: QRXWMOHMRWLFEY-UHFFFAOYSA-N
  • Mol. Mass: 137.1393
  • ALogP: -0.31
  • ChEMBL Molecule:
    isoniazid  
More Chemistry

Pharmacology

Drug Pricing (per unit)

Australia

$0.0824

United States

$0.0829 - $0.8309
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

( rifampin, isoniazid (nydrazid) )
|
( rifampin, pyrazinamide (Aldinamide), isoniazid (nydrazid) )

Alternative names

4-pyridinecarbohydrazide | 4-pyridinecarboxylic hydrazide | armazid | dow-isoniazid | hyzyd | inh | isoniazid | isoniazide | isonicotinic acid hydrazide | isonicotinic hydrazide | isonicotinohydrazide | isonicotinoylhydrazide | isonicotinsaeurehydrazid | isonicotinylhydrazine | laniazid | nicotibine | nydrazid | pyridine-4-carboxylic acid hydrazide | rimifon | stanozide

Organizations (279)

Research & Development (254)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (25)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (37)

Approved Indications (2)


 

Tuberculosis

Tuberculosis, Pulmonary

Experimental Indications - Clinical Trial Phases 1-4 (37)


 

Abortion, Missed (Phase 4)

Acquired Immunodeficiency Syndrome (Phase 3)

Alcoholism (Phase 4)

Antibiotic Prophylaxis (Phase 4)

Behavior, Addictive (Phase 4)

Brain Injuries, Traumatic (Phase 2)

Dermatology (Phase 4)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Diabetic Foot (Phase 2)

Drug Interactions (Phase 1)

Drug-Related Side Effects and Adverse Reactions (Phase 4)

Extensively Drug-Resistant Tuberculosis (Phase 3)

Healthy Volunteers (Phase 1)

Hepatitis (Phase 4)

HIV (Phase 3)

HIV Infections (Phase 4)

HIV Seropositivity (Phase 4)

Infertility, Female (Phase 4)

Latent Tuberculosis (Phase 4)

Leg Ulcer (Phase 2)

Opioid-Related Disorders (Phase 4)

Organ Transplantation (Phase 3)

Patient Compliance (Phase 4)

Pneumocystis Infections (Phase 2/Phase 3)

Pregnancy (Phase 1/Phase 2)

Prostheses and Implants (Phase 3)

Radiotherapy (Phase 4)

Renal Insufficiency (Phase 4)

Silicosis (Phase 3)

Tuberculosis ()

Tuberculosis, Female Genital (Phase 3)

Tuberculosis, Meningeal (Phase 2)

Tuberculosis, Multidrug-Resistant (Phase 3)

Tuberculosis, Pulmonary ()

Tuberculosis, Spinal (Phase 4)

Uveitis, Anterior (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 178
  • # of Trial Organizations: 254

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue